1. Hernandez Borrero, LJ, El-Deiry, WS. Tumor suppressor p53: biology, signaling pathways, and therapeutic targeting. Biochim Biophys Acta Rev Cancer. Aug 2021;1876(1):188556. doi:10.1016/j.bbcan.2021.188556
Google Scholar | Crossref | Medline2. Ozaki, T, Nakagawara, A. Role of p53 in cell death and human cancers. Cancers (Basel). Mar. 3 2011;3(1):994‐1013. doi:10.3390/cancers3010994
Google Scholar | Crossref | Medline3. Tessier-Cloutier, B, Kortekaas, KE, Thompson, E, et al. Major p53 immunohistochemical patterns in in situ and invasive squamous cell carcinomas of the vulva and correlation with TP53 mutation status. Mod Pathol. Aug 2020;33(8):1595‐1605. doi:10.1038/s41379-020-0524-1
Google Scholar | Crossref | Medline4. Kobel, M, Reuss, A, du Bois, A, et al. The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas. J Pathol. Oct 2010;222(2):191‐198. doi:10.1002/path.2744
Google Scholar | Crossref | Medline5. Kobel, M, Piskorz, AM, Lee, S, et al. Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma. J Pathol Clin Res. Oct 2016;2(4):247‐258. doi:10.1002/cjp2.53
Google Scholar | Crossref | Medline6. Casey, L, Kobel, M, Ganesan, R, et al. A comparison of p53 and WT1 immunohistochemical expression patterns in tubo-ovarian high-grade serous carcinoma before and after neoadjuvant chemotherapy. Histopathology. Nov 2017;71(5):736‐742. doi:10.1111/his.13272
Google Scholar | Crossref | Medline7. Singh, N, Piskorz, AM, Bosse, T, et al. P53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies. J Pathol. Mar 2020;250(3):336‐345. doi:10.1002/path.5375
Google Scholar | Crossref | Medline8. Kobel, M, Ronnett, BM, Singh, N, Soslow, RA, Gilks, CB, McCluggage, WG. Interpretation of P53 immunohistochemistry in endometrial carcinomas: toward increased reproducibility. Int J Gynecol Pathol. Jan 2019;38(Suppl 1):S123‐S131. doi:10.1097/PGP.0000000000000488
Google Scholar | Crossref | Medline9. Rabban, JT, Garg, K, Ladwig, NR, Zaloudek, CJ, Devine, WP. Cytoplasmic pattern p53 immunoexpression in pelvic and endometrial carcinomas with TP53 mutation involving nuclear localization domains: an uncommon but potential diagnostic pitfall with clinical implications. Am J Surg Pathol. Nov 2021;45(11):1441-1451. doi:10.1097/PAS.0000000000001713
Google Scholar | Crossref10. Grobner, SN, Worst, BC, Weischenfeldt, J, et al. The landscape of genomic alterations across childhood cancers. Nature. Mar. 15 2018;555(7696):321‐327. doi:10.1038/nature25480
Google Scholar | Crossref | Medline11. Ooms, AH, Gadd, S, Gerhard, DS, et al. Significance of TP53 mutation in wilms tumors with diffuse anaplasia: a report from the Children's Oncology group. Clin Cancer Res. Nov. 15 2016;22(22):5582‐5591. doi:10.1158/1078-0432.CCR-16-0985
Google Scholar | Crossref | Medline12. Maschietto, M, Williams, RD, Chagtai, T, et al. TP53 Mutational status is a potential marker for risk stratification in wilms tumour with diffuse anaplasia. PLoS One. 2014;9(10):e109924. doi:10.1371/journal.pone.0109924
Google Scholar | Crossref | Medline13. Gessi, M, von Bueren, AO, Rutkowski, S, Pietsch, T. P53 expression predicts dismal outcome for medulloblastoma patients with metastatic disease. J Neurooncol. Jan 2012;106(1):135‐141. doi:10.1007/s11060-011-0648-8
Google Scholar | Crossref | Medline14. Levine, AJ . Spontaneous and inherited TP53 genetic alterations. Oncogene. Oct 2021;40(41):5975-5983. doi:10.1038/s41388-021-01991-3
Google Scholar | Crossref15. Harris, CC . Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst. Oct. 16 1996;88(20):1442‐1455. doi:10.1093/jnci/88.20.1442
Google Scholar | Crossref | Medline16. Harms, KL, Chen, X. The functional domains in p53 family proteins exhibit both common and distinct properties. Cell Death Differ. Jun 2006;13(6):890‐897. doi:10.1038/sj.cdd.4401904
Google Scholar | Crossref | Medline17. Murnyak, B, Hortobagyi, T. Immunohistochemical correlates of TP53 somatic mutations in cancer. Oncotarget. Oct. 4 2016;7(40):64910‐64920. doi:10.18632/oncotarget.11912
Google Scholar | Crossref | Medline18. Kato, S, Han, SY, Liu, W, et al. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci U S A. Jul. 8 2003;100(14):8424‐8429. doi:10.1073/pnas.1431692100
Google Scholar | Crossref | Medline19. Gencel-Augusto, J, Lozano, G. P53 tetramerization: at the center of the dominant-negative effect of mutant p53. Genes Dev. Sep. 1 2020;34(17-18):1128‐1146. doi:10.1101/gad.340976.120
Google Scholar | Crossref | Medline20. Terek, RM, Healey, JH, Garin-Chesa, P, Mak, S, Huvos, A, Albino, AP. P53 mutations in chondrosarcoma. Diagn Mol Pathol. Feb 1998;7(1):51‐56. doi:10.1097/00019606-199802000-00009
Google Scholar | Crossref | Medline21. Xu, L, Chen, YT, Huvos, AG, et al. Overexpression of p53 protein in squamous cell carcinomas of head and neck without apparent gene mutations. Diagn Mol Pathol. Jun 1994;3(2):83‐92. doi:10.1097/00019606-199406000-00004
Google Scholar | Crossref | Medline22. Zhao, M, Zhang, NX, Laissue, JA, Zimmermann, A. Immunohistochemical analysis of p53 protein overexpression in liver cell dysplasia and in hepatocellular carcinoma. Virchows Arch. 1994;424(6):613‐621. doi:10.1007/BF00195775
Google Scholar | Crossref | Medline23. Mogaki, M, Hirota, M, Chaney, WG, Pour, PM. Comparison of p53 protein expression and cellular localization in human and hamster pancreatic cancer cell lines. Carcinogenesis. Dec 1993;14(12):2589‐2594. doi:10.1093/carcin/14.12.2589
Google Scholar | Crossref | Medline24. Brambilla, E, Gazzeri, S, Moro, D, et al. Immunohistochemical study of p53 in human lung carcinomas. Am J Pathol. Jul 1993;143(1):199‐210.
Google Scholar | Medline25. Lang, P, Maurer, J, Hoher, D, et al. Mutation and expression of the p53 tumor suppressor gene in tumor samples and cancer cell-lines - comparison of nonisotopic direct DNA-sequencing, immunoblotting and immunohistochemistry. Int J Oncol. Mar 1993;2(3):347‐355. doi:10.3892/ijo.2.3.347
Google Scholar | Crossref | Medline26. Stopera, SA, Bird, RP. Immunohistochemical demonstration of mutant p53 tumour suppressor gene product in aberrant crypt foci. Cytobios. 1993;73(293):73‐88.
Google Scholar | Medline27. Urano, Y, Oura, H, Sakaki, A, et al. Immunohistological analysis of P53 expression in human skin tumors. J Dermatol Sci. Sep 1992;4(2):69‐75. doi:10.1016/0923-1811(92)90061-f
Google Scholar | Crossref | Medline28. Cunningham, J, Lust, JA, Schaid, DJ, et al. Expression of p53 and 17p allelic loss in colorectal carcinoma. Cancer Res. Apr. 1 1992;52(7):1974‐1980.
Google Scholar | Medline29. Caamano, J, Ruggeri, B, Momiki, S, Sickler, A, Zhang, SY, Klein-Szanto, AJ. Detection of p53 in primary lung tumors and nonsmall cell lung carcinoma cell lines. Am J Pathol. Oct 1991;139(4):839‐845.
Google Scholar | Medline30. Tuncer, AM, Pakkala, S. Detection of p53 oncogene in acute-leukemia cells by immunoperoxidase technique. Acta Haematol. 1991;85(4):202‐205. doi:10.1159/000204893
Google Scholar | Crossref | Medline31. Arnold, MA, Schoenfield, L, Limketkai, BN, Arnold, CA. Diagnostic pitfalls of differentiating desmoplastic small round cell tumor (DSRCT) from wilms tumor (WT): overlapping morphologic and immunohistochemical features. Am J Surg Pathol. Sep 2014;38(9):1220‐1226. doi:10.1097/PAS.0000000000000231
Google Scholar | Crossref | Medline32. Wang, LL, Ji, ZH, Gao, Y, Chang, H, Sun, PP, Li, Y. Clinicopathological features of desmoplastic small round cell tumors: clinical series and literature review. World J Surg Oncol. Jun. 30 2021;19(1):193. doi:10.1186/s12957-021-02310-6
Google Scholar | Crossref | Medline33. Hamard, PJ, Lukin, DJ, Manfredi, JJ. P53 basic C terminus regulates p53 functions through DNA binding modulation of subset of target genes. J Biol Chem. Jun. 22 2012;287(26):22397‐22407. doi:10.1074/jbc.M111.331298
Google Scholar | Crossref | Medline34. Retzlaff, M, Rohrberg, J, Kupper, NJ, et al. The regulatory domain stabilizes the p53 tetramer by intersubunit contacts with the DNA binding domain. J Mol Biol. Jan. 9 2013;425(1):144‐155. doi:10.1016/j.jmb.2012.10.015
Google Scholar | Crossref | Medline35. Wolkowicz, R, Rotter, V. The DNA binding regulatory domain of p53: see the C. Pathol Biol (Paris). Dec 1997;45(10):785‐796.
Google Scholar | Medline36. Laptenko, O, Shiff, I, Freed-Pastor, W, et al The p53 C terminus controls site-specific DNA binding and promotes structural changes within the central DNA binding domain. Mol Cell. Mar 19 2015;57(6):1034 to 1046. doi:10.1016/j.molcel.2015.02.015
Google Scholar | Crossref | Medline